Organogenesis Holdings Inc.
ORGOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Organogenesis Holdings Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United. At a $288.2M market cap, Organogenesis Holdings Inc. ranks as a micro-cap company within healthcare. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chr.
Market Cap
$288.2M
Beta
1.31
P/E (TTM)
—
P/E (Fwd)
-8.15
EPS (TTM)
$-0.12
EPS (Fwd)
$-0.28
ROE
0.7%
ROA
2.1%
Cash
$91.4M
Total Debt
$70.9M
Free CF
$26.1M
52W Change
-21.7%
Annual Financials
Cash vs Debt
With $91.4M in cash and $70.9M in debt, ORGO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $26.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 0.7%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $450.9M (2022) to $563.0M (2025), reflecting a 25% increase over the period.
As with any equity investment, ORGO carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing ORGO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.